|D011658||Pulmonary Fibrosis NIH||0.26|
There is one clinical trial.
Emergent experimental and anecdotal evidence has indicated that critically ill COVID-19 patients demonstrate two patient sub-types (called phenotypes). In one group the disease progresses slowly and patients have a low potential of developing mild respiratory failure, but in the other group, an exaggerated immune response (hyper-inflammation/cytokine storm) may be linked to the onset of precipitous respiratory failure, termed acute respiratory distress syndrome. This syndrome is responsible for a large portion of COVID-19 associated mortality. Thus, determining links between hyper-inflammation and acute respiratory distress syndrome in COVID-19 patients is of immediate importance. Blood samples will undergo a number of analyses to help us to understand as much as possible about COVID-19. We will also study any differences in physiologic and cytokine levels before and after patients are treated with immunomodulatory therapies as part of clinical care in COVID-19 patients.
Description: Interleukin 1b, 6, 10 and tumor necrosis factor alphaMeasure: Inflammation Time: 24 hours
Description: Ratio of arterial oxygen tension (mmHg) to fraction of inspired oxygen (PaO2/FiO2)Measure: Oxygenation Time: 24 hours
Description: Pulmonary function tests (forced vital capacity (ml))Measure: Chronic Pulmonary outcomes Time: 8 to 12 weeks after discharge
Description: Pulmonary artery pressure (mmHg)Measure: Pulmonary artery pressure using transthoracic echocardiography Time: 8 to 12 weeks after discharge
Description: 6-minute walk testMeasure: Exertion Time: 8 to 12 weeks after discharge
Description: Short Form 36 (range 0 - 100)Measure: Quality of life assessment Time: 8 to 12 weeks after discharge
Description: Ventilator free daysMeasure: Duration of mechanical ventilation Time: 30 days
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports